Chloroquine for Treatment of Glioblastoma Multiforme
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Chloroquine is a strong lysosomotropic and DNA-intercalating agent in experimental studies
(Neurosurgical Focus 14(2): February, 2003) and an open-label clinical trial the
investigators have demonstrated a strong adjuvant effect of chloroquine on the therapy of
malignant gliomas. This study will assess in a randomized, placebo-controlled, double-blind
study the effects of chloroquine as adjuvant to the conventional therapy of Glioblastoma
Multiforme.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Neurology and Neurosurgery, Mexico